Harbor Capital Advisors Inc. Acquires 23,638 Shares of Cellebrite DI Ltd. $CLBT

Key Points

• Harbor Capital Advisors Inc. increased its stake in Cellebrite DI Ltd. by 19.4% in the second quarter, acquiring an additional 23,638 shares, bringing its total holdings to 145,692 shares.
• Cellebrite DI reported quarterly earnings of $0.12 EPS, exceeding expectations, with a revenue of $113.28 million, marking an 18.4% year-over-year increase.
• Recent analyst reports have lowered price targets for Cellebrite DI, with a consensus rating of "Buy" and an average price target of $22.40.

Harbor Capital Advisors Inc. grew its stake in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 19.4% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 145,692 shares of the company's stock after acquiring an additional 23,638 shares during the period. Harbor Capital Advisors Inc. owned about 0.06% of Cellebrite DI worth $2,331,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. OneDigital Investment Advisors LLC lifted its stake in shares of Cellebrite DI by 2.5% during the 1st quarter. OneDigital Investment Advisors LLC now owns 28,591 shares of the company's stock valued at $556,000 after buying an additional 688 shares in the last quarter. Bosun Asset Management LLC lifted its stake in shares of Cellebrite DI by 2.5% during the 1st quarter. Bosun Asset Management LLC now owns 44,376 shares of the company's stock valued at $862,000 after buying an additional 1,069 shares in the last quarter. Advisors Asset Management Inc. lifted its stake in shares of Cellebrite DI by 24.7% during the 1st quarter. Advisors Asset Management Inc. now owns 6,133 shares of the company's stock valued at $119,000 after buying an additional 1,214 shares in the last quarter. Assetmark Inc. purchased a new stake in shares of Cellebrite DI during the 1st quarter valued at approximately $33,000. Finally, HighTower Advisors LLC lifted its stake in shares of Cellebrite DI by 16.3% during the 1st quarter. HighTower Advisors LLC now owns 14,485 shares of the company's stock valued at $281,000 after buying an additional 2,029 shares in the last quarter. 45.88% of the stock is owned by institutional investors.

Cellebrite DI Trading Down 1.5%

Shares of NASDAQ:CLBT traded down $0.26 during midday trading on Friday, reaching $17.61. 1,577,074 shares of the company were exchanged, compared to its average volume of 1,815,467. The business's fifty day moving average is $15.43 and its two-hundred day moving average is $16.93. Cellebrite DI Ltd. has a one year low of $13.10 and a one year high of $26.30. The stock has a market cap of $4.22 billion, a PE ratio of -23.17, a price-to-earnings-growth ratio of 3.20 and a beta of 1.28.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last announced its earnings results on Thursday, August 14th. The company reported $0.12 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.01. The business had revenue of $113.28 million for the quarter, compared to the consensus estimate of $112.33 million. Cellebrite DI had a negative net margin of 34.56% and a positive return on equity of 23.92%. The business's revenue for the quarter was up 18.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.10 earnings per share. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, sell-side analysts expect that Cellebrite DI Ltd. will post 0.3 EPS for the current year.

Analyst Upgrades and Downgrades

CLBT has been the topic of a number of recent research reports. Needham & Company LLC dropped their price target on shares of Cellebrite DI from $24.00 to $18.00 and set a "buy" rating on the stock in a research note on Thursday, August 14th. Wall Street Zen cut shares of Cellebrite DI from a "buy" rating to a "hold" rating in a research note on Saturday, September 13th. Finally, Lake Street Capital lowered their target price on shares of Cellebrite DI from $24.00 to $22.00 and set a "buy" rating on the stock in a research note on Friday, August 15th. Five research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $22.40.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.